Can we individualise chemotherapy for colorectal cancer?

Open Access
Publisher Website
Google Scholar
Abstract
Colorectal cancer (CRC) is one of the leading malignancies in the Western World, responsible for ∼400 000 deaths each year [1, 2]. Despite radical surgery, more than half of CRC patients develop metastases, and palliative chemotherapy has been utilised to alleviate symptoms and prolong survival [3, 4]. The availability of newer and more efficacious agents over the last few years has seen an improvement in median overall survival in these patients, particularly when the three agents, 5-fluorouracil (5-FU), irinotecan and oxaliplatin, are all used at some stage in the clinical course [5–10].

This publication has 36 references indexed in Scilit: